Ozmosi | Tilarginine Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Tilarginine

Alternative Names: tilarginine
Clinical Status: Inactive
Latest Update: 2025-10-22
Latest Update Note: News Article

Product Description

Mechanisms of Action: NOS Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Arginox
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Shock, Cardiogenic|Myocardial Infarction

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

TRIUMPH Study

P3

Completed

Shock, Cardiogenic|Myocardial Infarction

2007-08-22

2025-07-04

Treatments

ARG-CS3-001

P3

Terminated

Shock, Cardiogenic|Myocardial Infarction

None

2019-03-21

Treatments